

CURRICULUM VITAE

NAME: **Richard David Graham LESLIE**

DOB: 26.4.49

DEGREES:	MRCS LRCP	University of London, UK	1972
	MB BS	University of London, UK	1972
	MD	University of London, UK	1980
	MRCP	Royal College of Physicians, London, UK	1974
	FRCP	Royal College of Physicians, London, UK	1989

GMC 1530399

Posts Held

1992 - Professor of Diabetes and Autoimmunity, St. Bartholomew's Hospital, London.

1982 - 1989 Wellcome Trust Senior Clinical Fellow and Consultant Physician, Departments of Medicine and Therapeutics, Westminster Hospital London and Departments of Diabetes and Medicine King's College Hospital, London.

1972 – 1982 House and Registrar, Westminster Hospital, King's College Hospital, London;

Achievements

- President of The Association of Physicians of Great Britain and Ireland 2012-2013
- Emeritus Professor Central South University, China and University of Rome, Italy.
- Visiting Professor, University of Chicago and University of Kansas, USA. Former Director, Mendel Institute, Rome, Italy
- Formerly Co-editor: Diabetes, Metabolism. Research. Reviews; Reviews Editor Diabetic Medicine Editorial Board: Diabetes Care.
- Principal Investigator – British Diabetic Twin Study; T1DUK Consortium; EU Action LADA, EU BLUEPRINT and EU EXALT. Founding Chairman, T1DUK Consortium.
- Invited lectures including: Royal College of Physicians Lecture (London); Silver Jubilee Oration (India); Niall O'Meara and Lily Lectures (Ireland), Xiangya Lecture (China). Senior Examiner: Chinese University, Hong Kong (2013).
- Wellcome Trust Senior Fellow in Clinical Science (1982 – 1992)
- Medical Research Council Travelling Fellow (1979 – 1980)
- Royal College of Physicians Samuel Leonard Simpson Fellowship in Endocrinology (1994)
- BMA Book of the Year Award (2009) *Clinical Endocrinology and Diabetes*, Elsevier, London.
- Published 12 books (9 as co-editor, 3 as author or co-author)
- Pathologist Power List (2015): Judged one of the world's '100 most influential people in laboratory medicine'.

Current Grants

EFSD (2018-2019) To study DNA methylation changes in immune effector cells and cord blood before the onset of Type 1 diabetes. **Leslie RD** Lernmark A Euros 100,000

European Union EUFP7 (2014-2019)

EXALT programme for thioredox vaccine therapy in type 1 diabetes Euros 0.5 million **Leslie RD** (Total to Consortium Euros 2.5 million)

Diabetes Twins Research Trust (2017-2019) Study of Identical twins with type 1 diabetes. £60,000

Leslie RD

DUK and JDRF (2015-2019) T1DUK Consortium: Immune therapy for Type 1 diabetes. **Leslie RD** (Total Funds to Consortium £4.5 million)

Selected Recent Publications from over 250 peer reviewed

Ibrahim M, Baker J, Cahn A, Eckel RH, El Sayed NA, Fischl AH, Gaede P, **Leslie RD**, Pieralice S, Tuccinardi D, Pozzilli P, Richelsen B, Roitman E, Standl E, Toledano Y, Tuomilehto J, Weber SL, Umpierrez GE. Hypoglycaemia and its management in primary care setting. *Diabetes Metab Res Rev.* 2020 Apr 28:e3332

Cardona A, Day FR, Perry JRB, Loh M, Chu AY, Lehne B, Paul DS, Lotta LA, Stewart ID, Kerrison ND, Scott RA, Khaw KT, Forouhi NG, Langenberg C, Liu C, Mendelson MM, Levy D, Beck S, **Leslie RD**, Dupuis J, Meigs JB, Kooner JS, Pihlajamäki J, Vaag A, Perflyev A, Ling C, Hivert MF, Chambers JC, Wareham NJ, Ong KK. Epigenome-Wide Association Study of Incident Type 2 Diabetes in a British Population: EPIC-Norfolk Study. *Diabetes*. 2019 Dec;68(12):2315-2326.

Xiang Y, Huang G, Zhu Y, Zuo X, Liu X, Feng Q, Li X, Yang T, Lu J, Shan Z, Liu J, Tian H, Ji Q, Zhu D, Ge J, Lin L, Chen L, Guo X, Zhao Z, Li Q, Weng J, Jia W, Liu Z, Ji L, Yang W, **Leslie RD**, Zhou Z; China National Diabetes and Metabolic Disorders Study Group. Identification of autoimmune type 1 diabetes and multiple organ-specific autoantibodies in adult-onset non-insulin-requiring diabetes in China: A population-based multicentre nationwide survey. *Diabetes Obes Metab*. 2019 Apr;21(4):893-902.

Pozzilli P, **Leslie RD**, Peters AL, Buzzetti R, Shankar SS, Milicevic Z, Pavo I, Lebrec J, Martin S, Schloot NC. Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, -4 and -5 Trials. *Diabetes Obes Metab*. 2018 Jun;20(6):1490-1498.

Achenbach P, Hawa MI, Krause S, Lampasona V, Jerram ST, Williams AJK, Bonifacio E, Ziegler AG, **Leslie RD**; Action LADA consortium. Autoantibodies to N-terminally truncated GAD improve clinical phenotyping of individuals with adult-onset diabetes: Action LADA 12. *Diabetologia*. 2018 Apr 4.

Napoli N, Strollo R, Defeudis G, Leto G, Moretti C, Zampetti S, D'Onofrio L, Campagna G, Palermo A, Greto V, Manfrini S, Hawa MI, **Leslie RD**, Pozzilli P, Buzzetti R; NIRAD (NIRAD 10) and Action LADA Study Groups. Serum Sclerostin and Bone Turnover in Latent Autoimmune Diabetes in Adults. *J Clin Endocrinol Metab*. 2018 May 1;103(5):1921-1928.

Pozzilli P, **Leslie RD**, Peters AL, Buzzetti R, Shankar SS, Milicevic Z, Pavo I, Lebrec J, Martin S, Schloot NC. Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, -4 and -5 Trials. *Diabetes Obes Metab*. 2018 Jun;20(6):1490-1498.

Leslie RD, Grant SFA. Teasing Diabetes Apart, One Locus at a Time. *Diabetes Care*. 2018 Feb;41(2):224-226.

Hernández M, López C, Real J, Valls J, Ortega-Martinez de Victoria E, Vázquez F, Rubinat E, Granado-Casas M, Alonso N, Molí T, Betriu A, Lecube A, Fernández E, **Leslie RD**, Mauricio D. Preclinical carotid atherosclerosis in patients with latent autoimmune diabetes in adults (LADA), type 2 diabetes and classical type 1 diabetes. *Cardiovasc Diabetol*. 2017 Jul 28;16(1):94.

Leslie RD, Jerram ST. Stratifying Diabetes: Desperately Seeking Specificity. *Diabetes*. 2017 Apr;66(4):801-803.

Mishra R, Chesi A, Cousminer DL, Hawa MI, Bradfield JP, Hodge KM, Guy VC, Hakonarson H; Bone Mineral Density in Childhood Study., Mauricio D, Schloot NC, Yderstræde KB, Voight BF, Schwartz S, Boehm BO, **Leslie RD***, Grant SFA*. *(co-corresponding and senior authors). Relative contribution of type 1 and type 2 diabetes loci to the genetic etiology of adult-onset, non-insulin-requiring autoimmune diabetes. *BMC Med*. (2017) Apr 25;15(1):88.

Paul DS, Teschendorff AE, Dang MA, Lowe R, Hawa MI, Ecker S, Beyan H, Cunningham S, Fouts AR, Ramelius A, Burden F, Farrow S, Rowlston S, Rehnstrom K, Frontini M, Downes K, Busche S, Cheung WA, Ge B, Simon MM, Bujold D, Kwan T, Bourque G, Datta A, Lowy E, Clarke L, Flicek P, Libertini E, Heath S, Gut M, Gut IG, Ouwehand WH, Pastinen T, Soranzo N, Hofer SE, Karges B, Meissner T, Boehm BO, Cilio C, Elding Larsson H, Lernmark Å, Steck AK, Rakyan VK, Beck S, **Leslie RD**. Increased DNA methylation variability in type 1 diabetes across three immune effector cell types. *Nat Commun*. (2016); 7:13555. doi: 10.1038/ncomms13555

Stunnenberg HG; International Human Epigenome Consortium, Hirst M.: A Blueprint for Scientific Collaboration and Discovery. *Cell*. (2016);167(5):1145-1149. doi: 10.1016/j.cell.2016.11.007.

Leslie RD, Palmer J, Schloot NC, Lernmark A. Diabetes at the crossroads: relevance of disease classification to pathophysiology and treatment. *Diabetologia*. (2016); 59: 13-20.

Schloot NC, Pham MN, Hawa MI, Pozzilli P, Scherbaum WA, Schott M, Kolb H, Hunter S, Scherthaner G, Thivolet C, Seissler J, **Leslie RD**; Action LADA Group. Inverse Relationship Between Organ-Specific Autoantibodies and Systemic Immune Mediators in Type 1 Diabetes and Type 2 Diabetes: Action LADA 11. *Diabetes Care* (2016); 39(11):1932-1939

Wang B, Hawa MI, Rijdsdijk FV, Fain PR, Paschou SA, Boehm BO, Steck AK, Snieder H, **Leslie RD**. Heritability of thyroid peroxidase autoantibody levels in type 1

diabetes: evidence from discordant twin pairs. *Diabetologia* (2015); 58(9):2079-86.